The Relationship Between Glycated Hemoglobin Levels and In-Stent Restenosis After Percutaneous Coronary Intervention in Patients with Coronary Artery Disease - Takeaways - MDSpire

The Relationship Between Glycated Hemoglobin Levels and In-Stent Restenosis After Percutaneous Coronary Intervention in Patients with Coronary Artery Disease

  • By

  • Yuyang Lei

  • Ping Jin

  • Hui Liu

  • Lin Su

  • Di Wu

  • Chenxi Sun

  • Haoyu Wu

  • Juan Zhou

  • Chen Wang

  • April 23, 2026

  • 0 min

Share

  • 1

    Higher glycated hemoglobin (HbA1c) levels are significantly associated with an increased risk of in-stent restenosis (ISR) in coronary artery disease patients post-PCI.

  • 2

    In a study of 6297 CAD patients, 20.72% were diagnosed with ISR, with higher HbA1c levels correlating to greater ISR risk.

  • 3

    Patients with HbA1c levels ≥6.5% exhibited a substantially higher ISR risk, with an odds ratio of 1.70 after adjusting for confounders.

  • 4

    The analysis revealed a non-linear relationship between HbA1c levels and ISR risk, with a threshold effect identified at an HbA1c level of 7.8%.

  • 5

    This study highlights the importance of monitoring HbA1c levels for predicting ISR risk in CAD patients undergoing percutaneous coronary intervention.

Original Source(s)

The Relationship Between Glycated Hemoglobin Levels and In-Stent Restenosis After Percutaneous Coronary Intervention in Patients with Coronary Artery Disease

  • by Yuyang Lei, Ping Jin, Hui Liu, Lin Su, Di Wu, Chenxi Sun, Haoyu Wu, Juan Zhou, Chen Wang

  • April 23, 2026

Related Content

Association Between Metabolic Clusters and Microbial Age in High-Risk Populations for Diabetes and Their Potential Impact on Cardiovascular Disease Risk: Cross-Sectional Observational Study

Learning curve of distal transradial access for coronary intervention: a single-center retrospective study

Combination Therapy Shows Potential in Psoriasis, Obesity

Researchers assess whether adding tirzepatide to ixekizumab affects skin and weight outcomes in adults with moderate to severe plaque psoriasis.